Champions Oncology posted a 9% revenue increase to $15.2 million in Q1 fiscal 2027, driven by improved service margins and a surge in data licensing revenue that surpassed the total for all of fiscal 2026.
Champions Oncology reported strong Q1 FY2027 earnings with revenue up 9%, margin expansion, and positive adjusted EBITDA.
Champions Oncology (CSBR) reported a strong start to fiscal 2027, with Q1 revenue rising 9% to $15.2 million. The company achieved its fifth consecutive quarter of positive adjusted EBITDA, which reached $671,000, supported by significant margin expansion in its translational oncology services division.
Margin expansion was primarily driven by bringing third-party radiolabeling capabilities in-house and leveraging higher revenue across the company's operating cost base.